[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Papaverine.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Papaverine.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Papaverine.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Papaverine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Papaverine.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Papaverine.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Papaverine.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Papaverine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Papaverine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Papaverine.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Papaverine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Papaverine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Papaverine.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Tolazoline is combined with Papaverine.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the orthostatic hypotensive activities of Papaverine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Papaverine.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Papaverine.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Papaverine.]
[C03AA06, trichlormethiazide, Papaverine may increase the hypotensive activities of Trichlormethiazide.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Papaverine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Papaverine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Papaverine.]
[C02BA01, trimethaphan, Papaverine may increase the hypotensive activities of Trimethaphan.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Papaverine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Papaverine.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Papaverine is combined with Azilsartan medoxomil.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Vandetanib.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Papaverine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Papaverine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Papaverine.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.]
[C04AX07, vincamine, Papaverine may increase the hypotensive activities of Vincamine.]
[C03BA10, xipamide, Papaverine may increase the hypotensive activities of Xipamide.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Vemurafenib.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Papaverine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ziprasidone.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Papaverine.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Papaverine.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Papaverine.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Papaverine.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Papaverine.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Papaverine.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Papaverine.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Papaverine.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Papaverine.]
[C08CA13, lercanidipine, The risk or severity of adverse effects can be increased when Lercanidipine is combined with Papaverine.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Papaverine.]
[G04BE03, sildenafil, The risk or severity of hypotension can be increased when Sildenafil is combined with Papaverine.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Papaverine.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Papaverine.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Papaverine.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Papaverine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Papaverine.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Bepridil.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Papaverine is combined with Riociguat.]
[C02KX04, macitentan, Papaverine may increase the hypotensive activities of Macitentan.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Papaverine is combined with Acebutolol.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Papaverine.]
[C02CC01, bethanidine, Papaverine may increase the hypotensive activities of Bethanidine.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Papaverine.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Papaverine.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Eliglustat.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Papaverine.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Panobinostat.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Papaverine.]
[B01AC27, selexipag, Papaverine may increase the hypotensive activities of Selexipag.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Papaverine.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Papaverine is combined with Bromocriptine.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Papaverine.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Amlodipine is combined with Papaverine.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Bumetanide is combined with Papaverine.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Papaverine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Papaverine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Papaverine.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Papaverine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Papaverine.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ribociclib.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Papaverine.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Benazepril is combined with Papaverine.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Papaverine.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Papaverine.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Papaverine.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Papaverine.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Papaverine.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Papaverine.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Papaverine is combined with Nesiritide.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Papaverine.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Papaverine.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Papaverine is combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Macimorelin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Papaverine.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Papaverine is combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Papaverine.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Encorafenib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Papaverine.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ivosidenib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Papaverine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Papaverine.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Papaverine.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Papaverine is combined with Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Papaverine.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Papaverine.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Clarithromycin.]
[C09CA06, candesartan, Papaverine may increase the hypotensive activities of Candesartan.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Papaverine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Entrectinib.]
[N07XX11, pitolisant, Papaverine may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Papaverine.]
[C03AA09, cyclothiazide, Papaverine may increase the hypotensive activities of Cyclothiazide.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Papaverine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dexchlorpheniramine.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Papaverine.]
[C08CA16, clevidipine, The risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Papaverine.]
[C02AA06, methoserpidine, Papaverine may increase the hypotensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Papaverine is combined with Opicapone.]
[C08CA17, levamlodipine, Papaverine may increase the hypotensive activities of Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Papaverine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Papaverine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Papaverine.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Papaverine.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Papaverine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Papaverine.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Papaverine.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Papaverine.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Papaverine is combined with Vericiguat.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Papaverine.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Fenoldopam is combined with Papaverine.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Papaverine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Papaverine.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Papaverine.]
[H04AA02, dasiglucagon, Papaverine may increase the hypotensive activities of Dasiglucagon.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Papaverine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Papaverine.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Papaverine.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Papaverine is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Clemastine.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Papaverine.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Papaverine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Papaverine.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Clomipramine.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Clonidine is combined with Papaverine.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Papaverine.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Papaverine.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Papaverine.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Cocaine.]
[C02KB01, metyrosine, Papaverine may increase the hypotensive activities of Metyrosine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Papaverine.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Papaverine.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Papaverine.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Papaverine.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Papaverine.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Papaverine.]
[C08CA09, lacidipine, Papaverine may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Papaverine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Papaverine.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Papaverine.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Lisinopril is combined with Papaverine.]
[C08CA11, manidipine, Papaverine may increase the hypotensive activities of Manidipine.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Papaverine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Papaverine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Papaverine.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Eplerenone is combined with Papaverine.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Melperone.]
[C03AA07, cyclopenthiazide, Papaverine may increase the hypotensive activities of Cyclopenthiazide.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Papaverine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Papaverine.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Papaverine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Papaverine.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Papaverine.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Papaverine is combined with Moxonidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Papaverine.]
[C02CC04, debrisoquin, Papaverine may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Papaverine.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Papaverine is combined with Nebivolol.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Papaverine.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Papaverine.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Papaverine.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Papaverine is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Papaverine.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Papaverine is combined with Diazoxide.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Papaverine is combined with Diclofenamide.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Papaverine.]
[C02DG01, pinacidil, Papaverine may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Papaverine.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Papaverine is combined with Pipamperone.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Erlotinib.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Papaverine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Papaverine.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Papaverine.]
[C02DB01, dihydralazine, Papaverine may increase the hypotensive activities of Dihydralazine.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Papaverine.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Papaverine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Papaverine.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Papaverine.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Papaverine.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Quinapril is combined with Papaverine.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Papaverine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Papaverine.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Papaverine.]
[N05AX08, risperidone, Papaverine may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Papaverine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Papaverine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Papaverine.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Papaverine.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Papaverine.]
[G04BE08, tadalafil, Papaverine may increase the hypotensive activities of Tadalafil.]
[C02KX02, ambrisentan, Papaverine may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Papaverine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Papaverine.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Domperidone.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Papaverine.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Papaverine.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Papaverine.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Papaverine.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Papaverine.]
[C09AA11, spirapril, Papaverine may increase the hypotensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Sultopride.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Papaverine.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Temafloxacin.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Papaverine is combined with Terazosin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Terodiline.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Enalapril is combined with Papaverine.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Papaverine.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Papaverine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of adverse effects can be increased when Torasemide is combined with Papaverine.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Trandolapril is combined with Papaverine.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Papaverine.]
[C02CA06, urapidil, Papaverine may increase the hypotensive activities of Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Papaverine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Papaverine.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Papaverine is combined with Barnidipine.]
[C09AA15, zofenopril, Papaverine may increase the hypotensive activities of Zofenopril.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Papaverine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Papaverine.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Papaverine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Papaverine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Valproic acid.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Papaverine.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Papaverine is combined with Amifostine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Papaverine.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Papaverine.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Papaverine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Papaverine.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Terfenadine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Papaverine.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Papaverine.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Papaverine.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Papaverine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Fendiline.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Papaverine.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Papaverine.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Flecainide.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Papaverine.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Papaverine.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Papaverine.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Papaverine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Flupentixol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Fluspirilene.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Papaverine.]
[C03CA01, furosemide, The risk or severity of adverse effects can be increased when Furosemide is combined with Papaverine.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Papaverine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Papaverine.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Papaverine.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Papaverine.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Papaverine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Papaverine.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Papaverine.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Papaverine.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Papaverine.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dofetilide.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Papaverine.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Papaverine.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Papaverine.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Fosinopril is combined with Papaverine.]
[S01EX01, guanethidine, Papaverine may increase the hypotensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Papaverine.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Papaverine is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Papaverine.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Quetiapine.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Papaverine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Papaverine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Oxatomide.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Perindopril is combined with Papaverine.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Papaverine is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Papaverine.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Papaverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Papaverine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Hydroxyzine.]
[C02AC06, rilmenidine, Papaverine may increase the hypotensive activities of Rilmenidine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Papaverine.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Imipramine is combined with Papaverine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Papaverine is combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Papaverine.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Papaverine.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Papaverine is combined with Indoramin.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Papaverine.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Anagrelide.]
[C07AA01, alprenolol, Papaverine may increase the hypotensive activities of Alprenolol.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Papaverine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Papaverine.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Papaverine is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Papaverine.]
[C01DA14, isosorbide mononitrate, Papaverine may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Papaverine.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Papaverine is combined with Isoxsuprine.]
[C02KD01, ketanserin, Papaverine may increase the hypotensive activities of Ketanserin.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Papaverine.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Papaverine.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mizolastine.]
[N04BC09, rotigotine, The risk or severity of adverse effects can be increased when Papaverine is combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Papaverine.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Labetalol is combined with Papaverine.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Papaverine.]
[C02AA05, deserpidine, Papaverine may increase the hypotensive activities of Deserpidine.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Papaverine.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be decreased when used in combination with Papaverine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Papaverine.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Papaverine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Papaverine.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Papaverine.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Papaverine.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Papaverine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Papaverine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Papaverine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Papaverine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Papaverine.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Papaverine.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Papaverine.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Papaverine.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Papaverine.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Methyldopa is combined with Papaverine.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Papaverine.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Papaverine.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Metolazone is combined with Papaverine.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Metoprolol is combined with Papaverine.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Papaverine.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mifepristone.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Papaverine.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Papaverine.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Papaverine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Papaverine.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Pazopanib.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Papaverine.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Papaverine.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Papaverine.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Papaverine is combined with Nadolol.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Papaverine.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Papaverine is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Papaverine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Papaverine.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Papaverine.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Papaverine.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Telmisartan is combined with Papaverine.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Papaverine.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Papaverine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Nifedipine.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Papaverine is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Papaverine.]
[C08CA07, nisoldipine, The risk or severity of adverse effects can be increased when Nisoldipine is combined with Papaverine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Papaverine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Papaverine.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Papaverine.]
[C02DD01, nitroprusside, The risk or severity of adverse effects can be increased when Nitroprusside is combined with Papaverine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Papaverine.]
[C02KX01, bosentan, Papaverine may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Papaverine.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Papaverine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ofloxacin.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Tamsulosin is combined with Papaverine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Papaverine.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Papaverine is combined with Oxprenolol.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Papaverine.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Asenapine.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Papaverine.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Papaverine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Papaverine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Papaverine is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Penfluridol.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Papaverine.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Papaverine.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Papaverine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Papaverine.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Papaverine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Papaverine.]
[V03AB36, phentolamine, The risk or severity of adverse effects can be increased when Phentolamine is combined with Papaverine.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Papaverine.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Saquinavir.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Eprosartan is combined with Papaverine.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Grepafloxacin.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Irbesartan is combined with Papaverine.]
[C03AA05, polythiazide, Papaverine may increase the hypotensive activities of Polythiazide.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Papaverine.]
[C07AB01, practolol, Papaverine may increase the hypotensive activities of Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Papaverine.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Papaverine.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Prenylamine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Papaverine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Papaverine.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Procainamide.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Papaverine.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Papaverine.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Papaverine.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Papaverine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Papaverine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Propafenone.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Papaverine.]
[C07AA05, propranolol, The risk or severity of adverse effects can be increased when Propranolol is combined with Papaverine.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Papaverine is combined with Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Papaverine.]
[N05AX12, aripiprazole, Aripiprazole may increase the hypotensive activities of Papaverine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Papaverine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Quinine.]
[C02AA01, rescinnamine, Papaverine may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Papaverine.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Papaverine.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Papaverine.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Papaverine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Papaverine is combined with Obinutuzumab.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Sotalol.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Papaverine.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
